Cellular and clinical pharmacology of fludarabine

Clinical Pharmacokinetics

Volumn 41, Issue 2, 2002, Pages 93-103

  Gandhi, Varsha ^a   Plunkett, William ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELL DNA; CYTARABINE TRIPHOSPHATE; DEOXYCYTIDINE KINASE; DNA PRIMASE; FLUDARABINE; FLUDARABINE TRIPHOSPHATE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; RIBONUCLEOTIDE REDUCTASE;

ACUTE LEUKEMIA; B CELL LEUKEMIA; B CELL LYMPHOMA; BOLUS INJECTION; COMBINATION CHEMOTHERAPY; DNA SYNTHESIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG ELIMINATION; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW;

EID: 0036204648     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241020-00002     Document Type: Review

References (68)

1. Synthesis of potential anticancer agents X: 2-Fluoroadenosine
2. Some comparative studies of calf and chicken adenosine deaminase
3. Structural requirements for binding by adenosine deaminase
4. Specificity of adenosine deaminase toward adenosine and 2′-deoxyadenosine analogues
5. Structure-activity relationships and cross-resistance observed on evaluation of a series of purine analogs against experimental neoplasms
6. Metabolism of 2-fluoroadenosine by Ehrlich ascites cells
7. Incorporation of nucleosides into the nucleotide pools of human erythrocytes: Adenosine and its analogs
8. 2-Fluoroadenosine 3′-5′-monophosphate. A metabolite of 2-fluoroadenosine in mouse cytotoxic lymphocytes
9. Nucleosides of 2-fluoroadenine
10. 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma
11. Proposed mechanism of therapeutic selectivity of 9-β-D-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells
12. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward human lymphoblasts in vitro and toward murine L1210 leukemia in vivo
13. Difference in metabolism and cytotoxicity between 9-β-D-arabinofuranosyladenine and 9-β-D-arabinofuranosyl-2-fluoroadenine in human leukemic lymphoblasts
14. Nucleotide specificity of human deoxycytidine kinase
15. Deoxycytidine kinase from calf thymus: Substrate and inhibitor specificity
16. Metabolism and therapeutic efficacy of 9-β-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388
17. Biological activity of 9-β-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-D-arabinofuranosyladenine
18. Comparison of the toxicity and metabolism of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9-β-D-arabinofuranosyladenine in human lymphoblastoid cells
19. Action of 9-β-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism
20. Incorporation of 9-β-D-arabinofuranosyl-2-fluoroadenine into HL-60 cellular RNA and DNA
21. Inhibition of RNA transcription: A biochemical mechanism of fludarabine-induced apoptosis in chronic lymphocytic leukemia cells
22. Metabolism and action of fludarabine phosphate
23. Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine: A mechanism for cytotoxicity
24. Metabolism and action of purine nucleoside analogs
25. Interaction of 2-halogenated dATP analogs (F. Cl, and Br) with human DNA polymerases, DNA primase and ribonucleotide reductase
26. In vitro activity of 9-β-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells
27. Comparison of the actions of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9-β-D-arabinofuranosyladenine on target enzymes from mouse tumor cells
28. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: Implications for a continuous infusion schedule
29. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells
30. Fludarabine potentiates metabolism of arabinosylcytosine in patients with acute myelogenous leukemia during therapy
31. Incorporation of fludarabine and arabinosylcytosine 5′-triphosphates by DNA polymerase α: Affinity, interaction, and consequences
32. Primer RNA chain termination induced by 9-beta-D-arabinofuranosyl-2-fluoroadenine 5′-triphosphate: A mechanism for DNA synthesis inhibition
33. Inhibition of DNA primase by nucleoside triphosphates and their arabinofuranosyl analogs
34. Inhibition of the 3′→5′ exonuclease of human DNA polymerase epsilon by fludarabine-terminated DNA
35. Eukaryotic DNA ligases
36. Dual mode of inhibition of purified DNA ligase I from human cells by 9-beta-D-arabinofuranosyl-2-fluoroadenine triphosphate
37. Gene deletion, a mechanism of induced mutation by arabinofuranosyl-2-fluoroadenine
38. Fludarabine- and gemcitabine-induced apoptosis: Incorporation of analogs into DNA is a critical event
39. High molecular weight DNA fragmentation: A critical event in nucleoside analogue-induced apoptosis in leukemia cells
40. Biochemical characterization of the protein activity responsible for high molecular weight DNA fragmentation during drug-induced apoptosis
41. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis
42. Induction of an apoptotic program in cell-free extracts by 2-chloro-2′-deoxyadenosine 5′-triphosphate and cytochrome c
43. Nucleotide requirement for the in vitro activation of Apaf-1-mediated caspase pathway
44. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate
45. Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate (NSC 312887), a new purine antimetabolite
46. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate in patient with relapsed leukemia
47. Pharmacokinetic study of fludarabine phosphate (NSC 312887)
48. A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids
49. Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients
50. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias
51. Phase I clinical investigation of fludarabine phosphate by a loading-dose and continuous infusion schedule
52. Plasma and cellular bioavailability of oral fludarabine
53. Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule
54. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia
55. Fludarabine: A review of its pharmacological properties and therapeutic potential in malignancy
56. Cellular metabolism of nucleoside analogs in CLL: Implications for drug development
57. Fludarabine: Pharmacokinetics, mechanisms of action, and rationales for combination therapy
58. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia
59. Inhibition of fludarabine metabolism by arabinosylcytosine during therapy
60. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy
61. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent
62. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy
63. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: Pharmacokinetic, pharmacodynamic, and molecular interactions
64. Cellular pharmaco-dynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during phase I clinical trial in chronic myelogenous leukemia
65. Minimum dose of fludarabine for maximal modulation of arabinosylcytosine triphosphate in human leukemia blasts during therapy
66. Oral bioavailability of 2-F-ara-A from fludarabine phosphate capsules in dogs
67. A pharmacokinetic study of single doses of oral fludarabine phosphate
68. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia